KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Net: 2009-2025

Historic Receivables - Net for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to $5.7 billion.

  • Regeneron Pharmaceuticals' Receivables - Net fell 6.88% to $5.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 billion, marking a year-over-year decrease of 6.88%. This contributed to the annual value of $6.2 billion for FY2024, which is 9.61% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Receivables - Net of $5.7 billion as of Q3 2025, which was up 1.37% from $5.6 billion recorded in Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Receivables - Net peaked at $7.0 billion during Q2 2021, and registered a low of $4.2 billion during Q1 2021.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Receivables - Net value was $5.6 billion (recorded in 2025), while the average stood at $5.6 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Receivables - Net spiked by 251.51% in 2021, and later decreased by 26.25% in 2022.
  • Regeneron Pharmaceuticals' Receivables - Net (Quarterly) stood at $6.0 billion in 2021, then declined by 11.73% to $5.3 billion in 2022, then increased by 6.35% to $5.7 billion in 2023, then climbed by 9.61% to $6.2 billion in 2024, then dropped by 6.88% to $5.7 billion in 2025.
  • Its Receivables - Net was $5.7 billion in Q3 2025, compared to $5.6 billion in Q2 2025 and $5.6 billion in Q1 2025.